Navigation Links
Data Available From Erbitux Phase III Study in First-Line Treatment,of Advanced Lung Cancer

NEW YORK, July 12, 2007 /PRNewswire-FirstCall/ -- ImClone Systems Incorporated and Bristol-Myers Squibb Company today announced results from an open-label Phase III study of ERBITUX(R) (Cetuximab) plus a taxane and carboplatin in the first-line treatment for metastatic non-small cell lung cancer (NSCLC). The study did not meet its primary endpoint of progression-free survival (PFS) as assessed by an independent radiology review committee (IRRC). However, key secondary endpoints of the study, including response rate as assessed by the IRRC and PFS as assessed by clinical investigators, were statistically significant and favored the ERBITUX- containing arm.

Known as BMS CA225-099, this study included more than 600 patients from the United States and Canada and was one of several clinical trials intended to establish the role of ERBITUX in the treatment of advanced NSCLC. Data from the largest of these trials, an ongoing multinational Phase III study of ERBITUX plus cisplatin and vinorelbine intended to be the pivotal study for the ERBITUX NSCLC regulatory strategy, are not yet available.

"We consider lung cancer to be a high priority and await the results of other Phase II and Phase III evaluations of ERBITUX in the first- and second- line setting with chemotherapy regimens," stated Eric K. Rowinsky, M.D., Chief Medical Officer and Senior Vice President of ImClone Systems.

"Lung cancer is a devastating disease with few effective treatment options," said Martin Birkhofer, M.D., Vice President, Oncology Global Medical Affairs, Bristol-Myers Squibb. "Efforts to fully interpret these results are ongoing, and the companies plan to submit the data from this study to an upcoming medical meeting in 2007."

About Lung Cancer

The American Cancer Society estimates that in the U.S., more than 213,000 people will be diagnosed with lung cancer in 2007. Lung cancer is the leading cause of cance
'"/>




Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Positive Results Prompt US National Cancer Institute to Make Glivec Available to Patients in Post-Surgical GIST Study
2. Positive Results Prompt US National Cancer Institute to Make Gleevec Available To Patients in Post-Surgical Gist Study
3. Data Available from Erbitux Phase III Study in First-Line Treatment of Advanced Pancreatic Cancer
4. Survival Data Available From Erbitux Study in First-Line Treatment of Advanced Head and Neck Cancer
5. Survival Data Available from Erbitux Study in First-Line Treatment of Advanced Head and Neck Cancer
6. Extensive Clinical Data on Erbitux Presented at the 2007 ASCO Annual Meeting
7. Merck at ASCO 2007: Spectrum of Studies Reinforces Promise of Erbitux for Colorectal and Head and Neck Cancer Patients
8. Randomized Phase III Trial Showed Erbitux Significantly Improved Secondary Endpoints of Progression-Free Survival and Disease Control in Metastatic Colorectal Cancer Patients
9. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
10. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
11. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
Post Your Comments:
(Date:8/29/2014)... -- Research and Markets has announced the ... of Pharmaceutical Equipment Market in China, 2014-2018" report ... Trend Forecast of Pharmaceutical Equipment Market in ... pharmaceutical equipment industry in the aspects of ... business performance of domestic major enterprises, as well as ...
(Date:8/29/2014)... , Aug. 29, 2014  Unilife Corporation ("Unilife" ... announced today that it intends to release its financial ... ended June 30, 2014 after market trading ends on ... scheduled a conference call for 4:30 p.m. U.S. EDT ... at 6:30 a.m. AEST), to review the Company,s financial results, ...
(Date:8/29/2014)... 2014  Pacific Medical Data Solutions is excited to ... . The main website, along with the site,s blog, ... services and content relevant to the medical billing industry. ... viewers can now better understand how PMDS products help ... create a more visible platform about medical billing best ...
Breaking Medicine Technology:Research and Development Trend Forecast of Pharmaceutical Equipment Market in China, 2014-2018 2Unilife Corporation to Announce Financial Results for Fiscal Year 2014 Fourth Quarter and Year End on Tuesday, September 9, 2014 2PMDS Announces New Website 2
... 2011 Mylan Inc. (Nasdaq: MYL ) ... Matrix Laboratories Limited) has received approval for three antiretroviral ... Health Organization,s (WHO) Prequalification of Medicines Programme. The products ... Tablet, 100 mg (heat-stable), and Tenofovir Disoproxil Fumarate and ...
... Medical imaging has revolutionized healthcare and is essential ... Modern equipment and protocols ensure that patients, physicians, and ... radiation, while still providing accurate results and diagnostic information. ... medical procedure must be balanced with the benefits of ...
Cached Medicine Technology:Mylan Receives WHO Approval for Innovative 'Second-Line-in-a-Box' HIV/AIDS Treatment 2Mylan Receives WHO Approval for Innovative 'Second-Line-in-a-Box' HIV/AIDS Treatment 3Mylan Receives WHO Approval for Innovative 'Second-Line-in-a-Box' HIV/AIDS Treatment 4AAPM Cautions that Patients Should Not Forgo Essential Medical Imaging 2
(Date:8/29/2014)... 29, 2014 Dr. Parsa Mohebi M.D. has ... hair loss achieve great results in hair transplantation. One ... Transplant , an FUE method that harvests facial hair for ... method lets patients whose hair loss classification is 5 and ... is a great alternative for those advanced hair loss patients ...
(Date:8/29/2014)... Highly regarded audiologist , Dr. Mary Ann Larkin has ... four reports are titled:, , Revealing the Truth ... , The Top 5 Things You Should Know Before ... in Children , Dr. Mary Anne Larkin choose to ... confusion and misinformation about each them. The reports are available ...
(Date:8/29/2014)... 2014 Pursuing its deepest desires to ... unveil a stunning new design that promises to redefine ... highly notable surrogacy platform has witnessed a 42 percent ... visitors a month, the FindSurrogateMother.com community is formed by ... common goal — the precious gift of life. , ...
(Date:8/29/2014)... 29, 2014 (HealthDay News) -- If you have bunions, taking ... treatment later, an expert says. A bunion is a ... when bone or tissue moves out of place and extends ... can cause debilitating pain and may require surgery to correct, ... Medical Center in Freehold, N.J. To prevent bunions, avoid ...
(Date:8/29/2014)... August 29, 2014 - Despite US Preventive Services ... are many barriers, several of which may be ameliorated ... researchers at NYU Langone Medical Center published online August ... Medicine ( JGIM ). , David Levine, MD, ... Internal Medicine at NYU Langone, and colleagues found that ...
Breaking Medicine News(10 mins):Health News:Advanced Hair Loss Patients Can Now Qualify for Hair Transplants Using Facial Donor Hair 2Health News:Charleston SC Audiologist, Dr. Mary Ann Larkin Authors Four New Special Reports on Important Hearing Healthcare Topics 2Health News:Charleston SC Audiologist, Dr. Mary Ann Larkin Authors Four New Special Reports on Important Hearing Healthcare Topics 3Health News:FindSurrogateMother.com Set to Unveil Stunning New Design as Member Sign-ups Increase by 42% since January 2Health News:FindSurrogateMother.com Set to Unveil Stunning New Design as Member Sign-ups Increase by 42% since January 3Health News:Take Steps to Control Bunions 2Health News:Options for weight loss your primary care doctor might not know about 2
... Than 1,500 YMCAs Get Their Communities Moving During Week-Long Event; ... YMCAs Aim to Keep Communities Active Year-Round, WASHINGTON, ... logged during "America On the Move Week with the YMCA" ... More than 1,500 YMCAs nationwide reached out to their ...
... With an eye on curing diabetes, scientists at Washington ... transplanted embryonic pig pancreatic cells destined to produce insulin ... for risky immune suppression drugs that prevent rejection. , ... earliest stages of developing into pancreatic tissues. Within several ...
... it instead of traditional immune globulin injection , , THURSDAY, ... hepatitis A with the hepatitis A vaccine is as ... of immune globulin, a new study found. , Based ... and Prevention,s Advisory Committee on Immunization Practices now recommends ...
... Union Urges Congress to Enact HR 1174 (Murphy) ... WASHINGTON, Oct. 18 A new study that,estimates ... virulent,antibiotic-resistant infection acquired mostly in the hospital underscores,the ... patient infection,rates, according to Consumers Union, the nonprofit ...
... device evaluated in cadaver by leading spine ... ... CoreSpine Technologies LLC, an,emerging spinal device company located in Minneapolis, Minnesota ... first product in development is a complete nucleus removal,device that seeks ...
... Conseco, Inc. (NYSE:,CNO) will report results for the ... 31, 2007. The company will host a conference call ... November 1, 2007. The web cast of the ... the company,s website as follows:, http://investor.conseco.com . Listeners should ...
Cached Medicine News:Health News:YMCA's Activate America(R) Motivates More Than 1.3 Million People to Take 8 Billion Steps Toward a Healthier Lifestyle During 'America On the Move Week with the YMCA' 2Health News:YMCA's Activate America(R) Motivates More Than 1.3 Million People to Take 8 Billion Steps Toward a Healthier Lifestyle During 'America On the Move Week with the YMCA' 3Health News:YMCA's Activate America(R) Motivates More Than 1.3 Million People to Take 8 Billion Steps Toward a Healthier Lifestyle During 'America On the Move Week with the YMCA' 4Health News:Cross-species transplant in rhesus macaques is step toward diabetes cure for humans 2Health News:Cross-species transplant in rhesus macaques is step toward diabetes cure for humans 3Health News:Hepatitis A Vaccine Best Bet to Treat Virus 2Health News:Hepatitis A Vaccine Best Bet to Treat Virus 3Health News:Alarming MRSA Infection Rates Underscore Need for Public Reporting of Hospital-Acquired Infections 2Health News:Alarming MRSA Infection Rates Underscore Need for Public Reporting of Hospital-Acquired Infections 3Health News:Initial Evaluation of New Nucleus Removal Device Provides Promising Results 2
... standard trial frames. They are made of optical quality ... box. There are two sets available providing a full ... is that a patient can wear the prism with ... the patient to adapt to the use of the ...
... C Dermatome - reaching a new evolutionary plateau. ... to operate in the pulse mode, or to ... entire instrument and hose assembly is autoclavable and ... 2-, 3-, or 4-inch widths. Simply select the ...
A finely parallel striated (scratched) clear plastic membrane encapsulated between glass plates....
BD Visitec IOL Manipulator (Fenzl), blunt tip angled 45, 12.0 mm from end, fits 0.20 mm diameter holes and larger (3/bx, 1 bx/ca). For positioning intraocular lenses. Sure grip handles hand ridge ind...
Medicine Products: